NCT01518907View on ClinicalTrials.gov

The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

PHASE1CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

February 28, 2013

Conditions
Edematous Fibrosclerotic PanniculopathyCellulite
Interventions
BIOLOGICAL

COLLAGENASE CLOSTRIDIUM HISTOLYTICUM

Subdermal dose

Trial Locations (1)

21201

SNBL Clinical Pharmacology Center, Inc, Baltimore

Sponsors
All Listed Sponsors
lead

Endo Pharmaceuticals

INDUSTRY